Spain connects medicine cost-effectiveness unit to economic austerity push
This article was originally published in Scrip
Executive Summary
In what appears to be the most nakedly overt connection between government desires to reduce medicines spending and the assessment of health technology, a new package of austerity measures approved yesterday by Spain's congress will – amongst other moves - include the creation of a new committee that will look at the cost-effectiveness of medicines and healthcare products.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.